These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 19014324)

  • 1. The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.
    Sassani JW; Mc Laughlin PJ; Zagon IS
    J Diabetes Res; 2016; 2016():9703729. PubMed ID: 27703986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of the OGF-OGFr pathway correlates with elevated serum OGF and ocular surface complications in the diabetic rat.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2020 Sep; 245(15):1414-1421. PubMed ID: 32640891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting OGF/OGFR signal to mitigate doxorubicin-induced cardiotoxicity.
    Chen X; Jian D; Xing J; Cheng X; Wang C; Wang C; Pan J; Qi X; Wang S; Li Z; Liu Y; Jian L; Tang H
    Free Radic Biol Med; 2024 Oct; 223():398-412. PubMed ID: 39122201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.
    Purushothaman I; Zagon IS; Sassani JW; McLaughlin PJ
    Biochem Pharmacol; 2021 Oct; 192():114712. PubMed ID: 34324868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Opioid Growth Factor in Growth Regulation and Immune Responses in Cancer.
    Hankins GR; Harris RT
    Adv Neurobiol; 2024; 35():45-85. PubMed ID: 38874718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective opioid growth factor receptor antagonists based on a stilbene isostere.
    Stockdale DP; Titunick MB; Biegler JM; Reed JL; Hartung AM; Wiemer DF; McLaughlin PJ; Neighbors JD
    Bioorg Med Chem; 2017 Aug; 25(16):4464-4474. PubMed ID: 28693915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy.
    Ciwun M; Tankiewicz-Kwedlo A; Pawlak D
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next Generation Sequencing and Association Studies in Familial Nonmedullary Thyroid Carcinoma: Let's Choose Appropriate Controls.
    Cazabat L; Terray A; de Mazancourt P; Ropers J; Groussin L; Raffin-Sanson ML
    Eur Thyroid J; 2017 Jul; 6(4):221-224. PubMed ID: 28868263
    [No Abstract]   [Full Text] [Related]  

  • 10. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of opioid receptor blockade determines biotherapeutic response.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid growth factor and the treatment of human pancreatic cancer: a review.
    Zagon IS; McLaughlin PJ
    World J Gastroenterol; 2014 Mar; 20(9):2218-23. PubMed ID: 24605021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.
    Budka J; Debowski D; Mai S; Narajczyk M; Hac S; Rolka K; Vrettos EI; Tzakos AG; Inkielewicz-Stepniak I
    Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the growth of human melanoma cells by methionine enkephalin.
    Wang DM; Wang GC; Yang J; Plotnikoff NP; Griffin N; Han YM; Qi RQ; Gao XH; Shan FP
    Mol Med Rep; 2016 Dec; 14(6):5521-5527. PubMed ID: 27878237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer.
    Goldenberg D; Zagon IS; Fedok F; Crist HS; McLaughlin PJ
    Thyroid; 2008 Nov; 18(11):1165-70. PubMed ID: 19014324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.